Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study.

Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study.

Gianluca E M Boari, Giulia Chiarini, Silvia Bonetti, Paolo Malerba, Gianluca Bianco, Cristina Faustini, Federico Braglia-Orlandini, Daniele Turini, Vittoria Guarinoni, Michele Saottini, Sara Viola, Giulia Ferrari-Toninelli, Giancarlo Pasini, Bianca Bonzi, Paolo Desenzani, Claudia Tusi, Eros Zanotti, Marzia Santagiuliana, Damiano Rizzoni

The aim of the study was to assess the short-term consequences of SARS-CoV-2-related pneumonia, also in relation to radiologic/laboratory/clinical indices of risk at baseline. This prospective follow-up cohort study included 94 patients with confirmed COVID-19 admitted to a medical ward at the Montichiari Hospital, Brescia, Italy from February 28th to April 30th, 2020. Patients had COVID-19 related pneumonia with respiratory failure. Ninety-four patients out of 193 survivors accepted to be re-evaluated after discharge, on average after 4 months. In ¼ of the patients an evidence of pulmonary fibrosis was detected, as indicated by an altered diffusing capacity of the lung for carbon monoxide (DLCO); in 6-7% of patients the alteration was classified as of moderate/severe degree. We also evaluated quality of life thorough a structured questionnaire: 52% of the patients still lamented fatigue, 36% effort dyspnea, 10% anorexia, 14% dysgeusia or anosmia, 31% insomnia and 21% anxiety. Finally, we evaluated three prognostic indices (the Brixia radiologic score, the Charlson Comorbidity Index and the 4C mortality score) in terms of prediction of the clinical consequences of the disease. All of them significantly predicted the extent of short-term lung involvement. In conclusion, our study demonstrated that SARS-CoV-2-related pneumonia is associated to relevant short-term clinical consequences, both in terms of persistence of symptoms and in terms of impairment of DLCO (indicator of a possible development of pulmonary fibrosis); some severity indices of the disease may predict short-term clinical outcome. Further studies are needed to ascertain whether such manifestations may persist long-term.

2021

covid-19, SARS-CoV-2, lung fibrosis, prognostic factors, sequelae, interstitial lung disease

10.1007/s40292-021-00454-w

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension